Proteome Sciences | GenomeWeb

Proteome Sciences

The company plans to use the money to speed its transition to a contract research business model, and to support its TMT reagents business.

The company hopes that looking at multiple species of the phosphorylated tau protein could allow for earlier and more accurate diagnosis of the disease.

The company, which has struggled to turn its broad proteomics expertise into steady profits, plans to focus more tightly on its pharma services business.

The firm is placing about 13.9 million new shares of its stock at 18 pence per share. 

The UK-based proteomics and lipidomics firm will offer solutions to help healthcare professionals utilizing protein expression data in patient care. 

Proteome Sciences this week lowered its full year 2014 guidance, citing delays in the timing of several contracts.

Proteome Sciences appointed Martin Diggle to its board as a non-executive director. Diggle is a director and partner at Vulpes Investment Management, where he manages the Vulpes Life Sciences Fund, which holds roughly 16 percent of Proteome Sciences’ ordinary shares.

NEW YORK (GenomeWeb News) – Proteome Sciences today said that revenues for the first half of 2014 were down 12 percent year over year.

NEW YORK (GenomeWeb) – Proteome Sciences said this week that it has signed a $2 million contract with Genting TauRx Diagnostic Centre, an affiliate of TauRx Therapeutics, to provide protein biomarker work in support of the company's Phase III trial of its Alzheimer's drug LMTX.

NEW YORK (GenomeWeb) – Proteome Sciences said today that it has signed a $2 million contract with Genting TauRx Diagnostic Centre, an affiliate of TauRx Therapeutics, to provide protein biomarker work in support of the company's Phase III trial of its Alzheimer's drug LMTX.

Pages

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.